RRM1和ERCC1在非小细胞肺癌中的表达及意义

被引：5

作者：

胡跃云 ^{[1
]}

张献波 ^{[1
]}

董英辉 ^{[1
]}

乞国艳 ^{[1
]}

张燕 ^{[1
]}

刘津来 ^{[1
]}

机构：

[1] 石家庄市第一医院

来源：

山东医药 | 2012年 / 21期

关键词：

癌; 非小细胞肺; DNA修复酶类; 预后; ERCC1; RRM1;

D O I：

暂无

中图分类号：

R734.2 [肺肿瘤];

学科分类号：

100214 ;

摘要：

目的探讨DNA修复基因家族成员ERCCl、RRM1在非小细胞肺癌(NSCLC)中的表达及意义。方法应用免疫组织化学PV-9000法对30例NSCLC患者肿瘤组织中的ERCC1、RRM1蛋白表达进行检测。用χ2检验、相关分析、Kaplan-Meier生存曲线进行统计分析。结果 NSCLC患者肿瘤组织中,ERCC1和RRM1表达与患者性别、年龄、分期、病理类型、是否吸烟等参数无明显相关;ERCC1和RRM1的表达呈正相关(r=0.439,P=0.027);ERCC1阴性组的总生存期和无疾病进展生存期均明显长于ERCC1阳性组,RRM1阴性组的总生存期和无疾病进展生存期均明显长于RRM1阳性组(P<0.05或<0.01)。结论 ERCC1和RRM1在NSCLC肿瘤组织中的表达具有相关性,ERCC1和RRM1低表达提示NSCLC患者生存期长、生活质量高,RRM1和ERCC1高表达者对吉西他滨+顺铂化疗耐药,可作为判断其预后的指标,指导临床个体化用药。

引用

页码：1 / 3

页数：3

共 13 条

[1] Gene smoking interaction associa-tions for the ERCC1 polymorphism in the risk of lung cancer. Zhou W,Liu G,Park S,et al. Cancer Epidermal Biomarkers Prev . 2005
[2] Gene expression as a predictive marker of outcome in stageⅡB-ⅢA-ⅢB non small cell lung cancer after induction gemcitabine-based chemotherapy followed by resection surgery. Rosell R,Felip E,Taron M,et al. Clinical Cancer Research . 2004
[3] Pharmacogenomics and gemcitabine. Rosell R,Cobo M,Isla D,et al. Annals of Oncology . 2006
[4] ERCC1and RRM1gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ceppi P,Volante M,Novello S,et al. Annals of Oncology . 2006
[5] Platinum resistance:the role of DNA repair pathways. Martin LP,Hamilton TC,Schilder RJ. Clinical Cancer Research . 2008
[6] Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Gossage L,Madhusudan S. Cancer Treatment Reviews . 2007
[7] Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Rosell R,Danenberg KD,Alberola V,et al. Clinical Cancer Research . 2004
[8] Targeted therapy in combination with gemcitabine in non-small cell lung cancer. R Rosell,L Crino,K Danenberg,G Scagliotti,G Bepler,M Taron,V Alberola,M Provencio,C Camps,F Marinis,JJ Sanchez,R Penas. Seminars in Oncology . 2003
[9] Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Li Q,Yu JJ,Mu C, et al. Anticancer Research . 2000
[10] Current status of excision repair cross complementing-group 1 (ERCC1) in cancer
Gossage, Lucy
Madhusudan, Srinivasan
[J]. CANCER TREATMENT REVIEWS, 2007, 33 (06) : 565 - 577

← 1 2 →